11
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Survey of animal drugs with carcinogenic propertiesFootnote

Pages 81-87 | Received 29 May 1984, Published online: 10 Jan 2009
 

Abstract

Residues of animal drugs with carcinogenic potential cannot always be avoided in food. The risk/benefit evaluation of carcinogenic drugs used in food‐producing animals is a scientifically unresolved problem. Nonetheless, a pragmatic solution taking into account such drugs’ putative mechanisms of action, their relative potency, and their significance in the prevention and therapy of disease must and can be achieved.

While it is unlikely that a new animal drug possessing overt carcinogenic properties would pass the approval process practiced in most countries today, a number of carcinogenic drugs for use in food‐producing animals are currently on the market. Their re‐evaluation from the viewpoint of human food safety is necessary, particularly if they are genotoxic (for example nitrofurans, nitroimidazoles, quinoxaline‐di‐N‐oxides). The carcinogenicity of hormonally active animal drugs, none of which has genotoxic potential, is believed to be related to their hormonal action. Thus, the establishment of a threshold level for these drugs and their residues appears possible. It is difficult to evaluate certain other nongenotoxic animal drugs which are carcinogenic at very high dose levels and in one species only. No carcinogenic substance, regardless of its hypothetical mechanism of action, should be used in food‐producing animals for which a very significant therapeutic benefit has not been demonstrated.

Notes

The term ‘animal drug’ refers in this paper to pharmacologically active substances used in animal husbandry, including in particular substances used to prevent or cure diseases, or to obtain other zoo‐technical benefits, regardless of whether they are divided into other categories (for example drugs and feed additives) by the regulations of different countries.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.